Inactive Instrument

Mithra Pharmaceuticals S.A. Euronext Bruxelles

MITRA

BE0974283153

Mithra Pharmaceuticals SA announced that it has received ?20 million in funding from Armistice Capital, LLC

Published on 08/27/2023 at 18:00

On August 28, 2023, Mithra Pharmaceuticals SA closed the transaction.

Latest news about Mithra Pharmaceuticals S.A.

Chart Mithra Pharmaceuticals S.A.

Duration

Period

MITRA: Dynamic Chart

Mithra Pharmaceuticals SA is a Belgian biopharmaceutical company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrolbased product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO.

Employees

270

Sector

Pharmaceuticals

Calendar

Sep. 18 - Q2 2025 Earnings Release (Projected)

More about the company